The Defense Health Agency awarded Twilight Neuroscience, Inc. a $300,387 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support an "Integrated Precision Immunology Approach for Developing an FC-Fusion Vaccine to Treat Frontotemporal Dementia." The grant, which runs from February 1, 2025 to January 31, 2027, will enable the company to conduct research and development aimed at creating a novel immunotherapeutic treatment for frontotemporal dementia, a type of neurodegenerative disorder. The Military Medical Research and Development program provides funding to academic institutions, research centers, and medical universities to pursue innovative biomedical studies across various medical disciplines, including neurological disorders.
Generated 3/4/25, 8:17 AM